Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.

NCT NCT06075537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Lead sponsor
Denali Therapeutics Inc.
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
September 20, 2023
Completion date
June 30, 2027
Enrollment
99 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis ii